These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 8582435)

  • 1. Biliary lipids, lithogenic index and biliary drug concentrations during etofibrate and bezafibrate treatment.
    Raedsch R; Plachky J; Wolf N; Simonis G
    Eur J Drug Metab Pharmacokinet; 1995; 20(2):113-8. PubMed ID: 8582435
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Abnormal lipid profiles on fibrate derivatives.
    McLeod AJ; Warren RJ; Armitage M
    Lancet; 1996 Jan; 347(8996):261. PubMed ID: 8551900
    [No Abstract]   [Full Text] [Related]  

  • 3. [The effect of bezafibrate on biliary lipids (author's transl)].
    Schlierf G; Fischer H; Roche A; Stiehl A; Oster P; Schellenberg B; Vollmar J
    MMW Munch Med Wochenschr; 1980 Feb; 122(5):165-8. PubMed ID: 6767944
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biliary lipid secretion in patients with heterozygous familial hypercholesterolemia and combined hyperlipidemia. Influence of bezafibrate and fenofibrate.
    Leiss O; Meyer-Krahmer K; von Bergmann K
    J Lipid Res; 1986 Jul; 27(7):713-23. PubMed ID: 3760707
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Bezafibrate and delayed action etofibrate in hyperlipidemia].
    Lang PD; Vollmar J
    Dtsch Med Wochenschr; 1983 Feb; 108(8):302-5. PubMed ID: 6825604
    [No Abstract]   [Full Text] [Related]  

  • 6. Effect of short-term treatment with bezafibrate and fenofibrate on biliary lipid metabolism in patients with hyperlipoproteinaemia.
    von Bergmann K; Leiss O
    Eur J Clin Invest; 1984 Apr; 14(2):150-4. PubMed ID: 6428905
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of etofibrate on bile production in the normolipidemic rat.
    Bocos C; Orozco E; Castro M; Quack G; Herrera E
    Gen Pharmacol; 1995 May; 26(3):537-42. PubMed ID: 7789727
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of etofibrate retard, bezafibrate and procetofen.
    Luley C; Schwartzkopff W; Schilling A; Calder D; Scheffler W
    Artery; 1980; 8(2):128-33. PubMed ID: 7458677
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of clinofibrate, a new hypolipidemic agent, on biliary and serum lipids in patients with hyperlipidemia.
    Takeuchi N; Kukita H; Kajiyama G; Fujiyama M; Ishikawa K; Miki H; Mishima T; Murata K; Asano T
    Atherosclerosis; 1982 Apr; 42(2-3):129-39. PubMed ID: 7073798
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of etofibrate on LDL-subtype distribution in patients with diabetic dyslipoproteinemia.
    Geiss HC; Dietlein M; Parhofer KG
    Exp Clin Endocrinol Diabetes; 2003 Sep; 111(6):322-4. PubMed ID: 14520596
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Evaluation of efficacy and safety of etofibrate in primary hyperlipidemia. A multicenter study].
    dos Santos JE; Loures-Vale AA; Novazzi JP; Rabelo LM; Martinez TL
    Arq Bras Cardiol; 1996 Dec; 67(6):419-22. PubMed ID: 9246832
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of bezafibrate, fenofibrate, nicotinic acid and etofibrate on plasma high-density lipoprotein levels.
    Paoletti R; Franceschini G; Sirtori CR
    Am J Cardiol; 1983 Aug; 52(4):21B-27B. PubMed ID: 6351577
    [No Abstract]   [Full Text] [Related]  

  • 13. Lipid profiles on fibric-acid derivatives.
    Capps NE
    Lancet; 1994 Sep; 344(8923):684-5. PubMed ID: 7915370
    [No Abstract]   [Full Text] [Related]  

  • 14. Effect of the type of dietary fat on biliary lipid composition and bile lithogenicity in humans with cholesterol gallstone disease.
    Yago MD; González V; Serrano P; Calpena R; Martínez MA; Martínez-Victoria E; Mañas M
    Nutrition; 2005 Mar; 21(3):339-47. PubMed ID: 15797676
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of Etofibrate (Lipo-Merz) on "in vitro" cellular immune response and on lipid parameters of men with myocardial infarction and with arteriosclerosis obliterans.
    Horváth M; Varsányl M; Jovanovich N; Romics L; Gerö S
    Allergol Immunopathol (Madr); 1990; 18(2):95-9. PubMed ID: 2371944
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bezafibrate therapy and biliary lipids: effects of short-term and long-term treatment in patients with various forms of hyperlipoproteinaemia.
    Eriksson M; Angelin B
    Eur J Clin Invest; 1987 Oct; 17(5):396-401. PubMed ID: 3121342
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative efficacy and safety of ciprofibrate and sustained-release bezafibrate in patients with type II hyperlipidaemia.
    Betteridge DJ; O'Bryan-Tear CG
    Postgrad Med J; 1996 Dec; 72(854):739-43. PubMed ID: 9015467
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fibrates modify the expression of key factors involved in bile-acid synthesis and biliary-lipid secretion in gallstone patients.
    Roglans N; Vázquez-Carrera M; Alegret M; Novell F; Zambón D; Ros E; Laguna JC; Sánchez RM
    Eur J Clin Pharmacol; 2004 Feb; 59(12):855-61. PubMed ID: 14685799
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Bile lipid composition in subjects with blood lipid disorders (types II and IV). Effect of a new hypolipemic drug (Etofibrate)].
    Altomonte L; Mingrone G; Ghirlanda G; Manna R; Rebuzzi A; Pala MA; Greco AV
    Minerva Med; 1980 Feb; 71(4):273-8. PubMed ID: 7354946
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differences between hepatic and biliary lipid metabolism and secretion in genetically gallstone-susceptible and gallstone-resistant mice.
    Xu G; Zhao L; Fuchs M
    Chin Med J (Engl); 2002 Sep; 115(9):1292-5. PubMed ID: 12411097
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.